Wilex improves result


Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight.
The 2011 total revenue was better than last year (€11.7m, 2010: €1.3m), with the licence agreement from Prometheus Inc. about a therapeutic antibody named Rencarex accounting for the biggest share: In April 2011, Wilex received €19m from the Californian company which in turn, secured the rights to promote the anti-cancer remedy in the US. After an FDA approval last autumn, Rencarex is now on an amended study protocol. If data are positive, Wilex could file for drug approval in Europe and the US in early 2013. As foreseen in the Prometheus deal, the Munich biotech start-up becomes eligible for a €20m payment at the end of April. Whether Wilex grabs the money or instead takes hold of the option to secure the marketing rights in Europe for one–yet unnamed–Prometheus product remains elusive so far.
Data on Wilex' second pipeline drug Mesupron is also nervously anticipated. In a clinical Phase II study, it is being tested on 132 patients with a certain type of breast cancer. The primary endpoint PFS will be accomplished in 2012, data for overall survival will likely be available in 2013. CFO Peter Llewellyn-Davies pointed out that Wilex had diversified its service portfolio: "In 2011 we successfully integrated two acquisitions." One of them, Heidelberg Pharma, is specialised in customer-oriented CR. The other, Oncogene Science successor Wiley Inc., does in vitro diagnostic tests. For 2012 sales are expected to grow from €11.7m up to €16m. However, the operating loss would still remain between €10m and €14m (2011:€13,4m). WestLB research analyst Mark Belsey reports that due to higher revenues and lower operating costs the FY-11 results were slightly better than he expected. For FY-12 his opinion is in line with the company's expectations: His sales forecast lies at €15.6m, EBIT guidance at €-12,7m.



Leverkusen - A short statement from the European Medicines Agency (EMA) and a big step for the German biotech Biofrontera. The agency issued a favourable opinion on Biofrontera's marketing approval application for its drug for...



Leverkusen/San Francisco - Bayer HealthCare and Onyx Pharmaceuticals will not to court over Nevaxar. The two companies reached an agreement related to regorafenib, a late-stage oncology compound. Regorafenib is an oral...



Ingelheim/Ridgefield –Boehringer Ingelheim’s COPD treatment Combivent Respimat has been approved by the U.S. Food and Drug Administration (FDA) for the US market. The new, propellant-free inhaler product for the beta adrenergic...



Rostock – German researchers say overexpression of one of the 49 transport proteins that shuttle substances over the blood-brain barrier could be the key to treating Alzheimer’s disease. In mice, the group headed by Jens Pahnke...



Rehovot/Monheim – Bayer Crop Science may be a step closer to introducing desirable traits in wheat. In the collaboration with Israeli Evogene Ltd. the German company has reached a milestone. Utilising Evogene‘s proprietary...



Willich – Brasilian biopolymer producer Braskem and German bioplastics compounding specialist FKuR GmbH, have signed a compounding agreement for green polyethylene. The tailor-made product will be a first in Europe, according...



Leverkusen - It was a black Tuesday for Bayer. After rumours were leaked out that the FDA has doubts over the German pharmaceutical company's potential blockbuster Xarelto, the shares temporarily dropped as much as 17 percent....



Bad Homburg - German VC firm Creathor venture announced the first closing of its Creathor Venture Fund III. Now, the company is poised to mete out €51million of fresh capital to start-ups. Life science companies will be among the...



Berlin – Despite intense marketing measures, revenues from Epigenomics’ Epi proColon bowel cancer test remain flat. Along with its QII/2011 numbers, the Berlin-based in vitro diagnostic specialist revealed strict cost-saving...

Displaying results 21 to 30 out of 454

< Previous 21-30 Next >

© 2007-2015 BIOCOM


Product of the week



All Events

Stock list

All quotes


  • MEDIGENE (D)10.45 EUR7.51%
  • WILEX (D)3.65 EUR5.49%
  • SUMMIT (UK)4.03 GBP3.87%


  • 4SC (D)4.59 EUR-6.33%
  • BAVARIAN NORDIC (D)41.82 EUR-6.28%
  • BIOFRONTERA (D)2.06 EUR-5.50%


  • DBV Technologies (F)52.75 EUR16.9%
  • Allergy Therapeutics (UK)23.50 GBP15.3%


  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.68 EUR-28.8%
  • NORDIC NANOVECTOR (N)25.20 NOK-26.5%


  • 4SC (D)4.59 EUR345.6%
  • ADOCIA (F)65.40 EUR336.0%
  • WILEX (D)3.65 EUR319.5%


  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)8.85 SEK-70.6%
  • NEOVACS (F)1.10 EUR-69.3%

No liability assumed, Date: 03.07.2015

Current issue

All issues